Intraosseous Infusion Kits Market Size

Intraosseous Infusion Kits Market Analysis

The intraosseous infusion kits market is anticipated to register a CAGR of nearly 7.2% during the forecast period.

• COVID-19 impacted market growth slightly due to the cancellations of elective procedures involving hospitalization other than COVID-19. However, the market growth recovered in the last few years since the restrictions were lifted. The new variants of COVID-19 have no significant impact on the studied market in the current scenario. Hence, the market is expected to register a stable growth rate during the forecast period.
• The advantages of intraosseous infusion (IO) over other routes of administration of drugs are expected to propel market growth. For instance, a research article published in the European Journal of Trauma and Emergency Surgery in February 2021 included nine studies comprising 1,218 trauma patients and 1,432 device insertions. The insertion success rate was 95%, and the incidence of complications was 0.9%. The article stated that intraosseous catheters have high insertion success rates and a low incidence of complications in trauma patients.
• Additionally, an article published in February 2022 by the National Center for Biotechnology Information (NCBI) stated that intraosseous infusion is an effective and safe technique, that increases patient survival. As a result, it is critical that all nursing professionals understand how to use the various intraosseous devices in situations where immediate peripheral venous access is not possible. The advantages and rising awareness about IO infusion are expected to propel the demand for IO infusion kits during the forecast period.
• Furthermore, the rising burden of arthritis and trauma is expected to propel the demand for IO infusion as these diseases are associated with difficulty in establishing venous access, which is made possible by the use of intraosseous needles. For instance, as per the Australian Bureau of Statistics 2023 update, one in eight (12.5%) people of all ages had arthritis in Australia in 2021. Additionally, as per versus arthritis 2022 report, 20.3 million people had a musculoskeletal (MSK) condition such as arthritis or back pain in the United Kingdom in 2021. Therefore, the high prevalence of arthritis worldwide is expected to propel the demand for IO infusion for the greater bioavailability of drugs for the treatment of diseases, thereby augmenting market growth.
• Therefore, owing to the aforementioned factors, such as the advantages of IO infusion and the high burden of arthritis worldwide, the studied market is anticipated to witness growth over the analysis period. However, the high cost associated with Procedures and stringent regulatory approvals and product recalls is expected to restrain the market growth.